Peptides for thyroid support — what the research has explored

The thyroid sits at one of the most consequential junctions in the endocrine system. It's not dramatic the way the adrenal glands can feel dramatic in a crisis, and it doesn't carry the weight that reproductive hormones carry culturally. But the thyroid sets the metabolic rate of virtually every cell in the body, and when its output is off — in either direction, by any amount — the consequences are pervasive and systemic in a way that is frustratingly easy to dismiss as vague.

The physiology is worth understanding before any conversation about interventions.

The thyroid makes two primary hormones: T4 (thyroxine) and T3 (triiodothyronine). T4 is the storage form — less biologically active, longer half-life, produced in much larger quantities. T3 is the active form — binds thyroid hormone receptors with far greater affinity, drives cellular metabolism, and is produced partly by the thyroid directly and partly by peripheral conversion of T4 in the liver, kidney, and other tissues. The ratio of T4 to T3, and the efficiency of that peripheral conversion, varies by individual and is affected by numerous factors including nutritional status (selenium is a cofactor for the deiodinase enzymes that convert T4 to T3), inflammation, illness, and certain medications.

The hypothalamic-pituitary-thyroid axis regulates all of this. The hypothalamus releases thyrotropin-releasing hormone — TRH — which signals the pituitary to release TSH. TSH travels to the thyroid and stimulates T4 and T3 production. When circulating thyroid hormone levels are adequate, they feed back to suppress both TRH and TSH. When they're low, TSH rises to stimulate more production. TSH is therefore an upstream amplification signal: elevated TSH tells you the system is working hard to drive more thyroid output; suppressed TSH tells you circulating thyroid hormone is sufficient or excessive.

Primary hypothyroidism — the most common form — is thyroid gland failure with normal or elevated TSH. Hashimoto's thyroiditis is the most common cause in the developed world: an autoimmune condition in which immune cells attack thyroid tissue, often over years or decades, gradually impairing gland function. Hashimoto's is characterized by positive thyroid peroxidase antibodies (TPO-Ab) and sometimes thyroglobulin antibodies, and it has a distinct inflammatory dimension that matters when thinking about adjunctive approaches. Secondary hypothyroidism, much less common, involves a failure at the pituitary or hypothalamus level — TSH may be inappropriately low even as thyroid hormone is deficient.

Hyperthyroidism presents the reverse picture: too much thyroid hormone, most commonly from Graves' disease — an autoimmune condition in which stimulating antibodies mimic TSH — or from thyroid nodules that produce hormone autonomously. The symptoms are nearly the mirror image of hypothyroidism: weight loss despite good appetite, heat intolerance, palpitations, anxiety, insomnia. Graves' disease also has an autoimmune dimension that is bidirectionally relevant to the immune-modulation question.

Low T3 syndrome — sometimes called euthyroid sick syndrome in acute illness contexts, and sometimes used more loosely to describe reduced peripheral T4-to-T3 conversion — describes a pattern where TSH and T4 appear normal but free T3 is low, symptoms of hypothyroidism are present, and the conventional management paradigm (which focuses primarily on TSH) doesn't address what may actually be a conversion problem. This pattern is frequently a point of friction between standard endocrinology, which may not treat on free T3 alone, and functional medicine, which often does.

The conventional management hierarchy is well-established and well-evidenced.

For primary hypothyroidism, levothyroxine — synthetic T4 — is the FDA-approved standard of care. It replaces the T4 that a failing thyroid no longer produces adequately, relies on peripheral conversion to T3, and has decades of safety and efficacy data behind it. For most patients, levothyroxine works well. It normalizes TSH, reverses the clinical hypothyroid syndrome, and is dosed reliably. The foundational nature of this treatment is not in question: thyroid hormone replacement when indicated is essential and is not a place where peptides or other adjunctive approaches can substitute.

The controversies in thyroid management arise at the margins, and they're real controversies, not just functional medicine noise. A subset of patients feel better on combination T4/T3 therapy — either levothyroxine plus liothyronine (synthetic T3) or natural desiccated thyroid (NDT), which contains both T4 and T3 from porcine thyroid. Standard endocrinology generally prefers levothyroxine monotherapy based on the available trial data; functional and integrative medicine practitioners often add T3 based on patient symptoms and free T3 levels. This is a genuine clinical debate without a clean resolution. For hyperthyroidism, antithyroid medications (methimazole, propylthiouracil), radioactive iodine (RAI) ablation, and thyroidectomy represent the definitive treatment options depending on the cause, severity, and patient factors.

Where does the peptide landscape actually intersect with thyroid biology?

The honest starting point is that peptides don't replace thyroid hormone, and the research doesn't suggest they should. The thyroid-peptide intersection is about the inflammatory and autoimmune dimensions, the nutritional and support factors, and some important interaction considerations.

Hashimoto's thyroiditis is, at its core, an inflammatory autoimmune process. The thyroid is being attacked by immune cells that shouldn't be attacking it. The autoimmune dimension makes it conceptually relevant to peptides with immunomodulatory properties. Thymosin Alpha-1 is researched for its regulatory effects on the immune system — it appears to support regulatory T cell (Treg) activity and to modulate the balance between inflammatory and tolerogenic immune responses. In the context of autoimmune thyroid disease, the theoretical interest is in whether normalizing immune dysregulation might slow the autoimmune attack on thyroid tissue. The evidence in Hashimoto's specifically is limited; Thymosin Alpha-1 has better-characterized evidence in viral hepatitis and immune-compromised contexts. Whether it has a meaningful role in Hashimoto's management is something your prescribing provider would need to evaluate in the context of your individual antibody levels and clinical picture.

KPV and VIP, both researched for anti-inflammatory properties, have theoretical relevance in the Hashimoto's inflammatory context through their effects on cytokine signaling. Systemic inflammation upregulates certain cytokines — particularly IL-6 — that impair peripheral T4-to-T3 conversion, so reducing the inflammatory burden is not purely an immune consideration; it has downstream effects on the thyroid hormone that actually reaches tissues. This is preclinical reasoning more than clinical evidence in thyroid disease specifically, but the mechanism is coherent.

BPC-157, researched for gut mucosal integrity and systemic healing effects in animal models, enters the thyroid conversation through the gut-thyroid connection. The gut microbiome affects thyroid hormone metabolism — bacterial deiodinases in the gut contribute to T4-to-T3 conversion and T3 enterohepatic circulation. Gut dysbiosis, by reducing this contribution, may impair the thyroid hormone picture. LPS from dysbiotic gut bacteria also contributes to systemic inflammation that impairs T4-to-T3 conversion. Again, this is mechanism-level reasoning rather than direct clinical trial evidence in thyroid patients.

Selenium deserves particular emphasis because it occupies the foundational nutritional territory that often gets overlooked when people go searching for more sophisticated interventions. The selenoenzymes — particularly the iodothyronine deiodinases that convert T4 to T3 — require selenium as a cofactor. Selenium deficiency impairs conversion and also allows oxidative damage to thyroid tissue, since glutathione peroxidase (another selenoenzyme) protects against the hydrogen peroxide the thyroid uses in hormone synthesis. Studies in Hashimoto's patients have found that selenium supplementation reduces TPO antibody levels over time — a finding replicated in multiple trials, making it one of the better-evidenced adjunctive interventions in Hashimoto's. Brazil nuts contain substantial selenium, but their content is highly variable; selenomethionine supplementation is more reliable for therapeutic purposes. This is not a peptide, but it belongs in any honest discussion of thyroid support.

Iodine is the other foundational piece — and a more complicated one. The thyroid requires iodine for hormone synthesis, and iodine deficiency causes hypothyroidism at the population level, which is why iodized salt was a major public health intervention. But excess iodine can trigger or worsen autoimmune thyroid disease in susceptible individuals, and supplementing iodine in Hashimoto's without medical guidance can worsen the autoimmune picture. This is a case where more is not better, and where self-directed supplementation carries real risk.

The interaction considerations with GH-axis peptides are clinically important and often not discussed. When GH secretion increases — either endogenously or through GH-axis peptides like sermorelin, ipamorelin, or CJC-1295 — IGF-1 rises. Elevated IGF-1 increases the activity of the deiodinase enzymes that convert T4 to T3, effectively increasing T3 availability. This means that starting GH-axis peptides in someone on a stable levothyroxine dose may shift their thyroid hormone balance — potentially requiring dose adjustment, particularly if they were previously symptomatic at the margin. This is not a contraindication, but it is a reason why thyroid labs should be monitored when initiating GH-axis therapy, and why a prescribing provider needs to see the full picture before recommending these compounds to a thyroid patient.

The GLP-1 agonist thyroid consideration is one of the most discussed safety questions in modern prescribing. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — carry an FDA warning about thyroid C-cell tumors because animal studies (primarily in rodents, which have high GLP-1 receptor expression in thyroid C-cells) showed increased rates of medullary thyroid carcinoma. The absolute risk in humans appears very low — human C-cells have much lower GLP-1 receptor expression — but the warning stands, and these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is a real consideration, not a theoretical one, and it belongs in any conversation with your prescribing provider before initiating GLP-1 therapy. It is not a reason to avoid these medications for everyone with any thyroid history, but it is a reason to disclose your full thyroid history — including nodules, previous thyroid surgery, family history, and antibody status — before any GLP-1 or GLP-1-adjacent peptide protocol.

The subclinical hypothyroidism question — the TSH that is above the upper range of normal (typically 4.5-5.0 mIU/L depending on the lab) but below the level where most providers treat — is one of the most common points of frustration in thyroid care. Standard endocrinology generally does not treat subclinical hypothyroidism below a TSH of around 10 mIU/L unless there are specific circumstances: pregnancy or conception planning, significant symptoms, or high TPO antibody levels. Functional medicine often treats at lower TSH thresholds. The patient often feels unclearly unwell. The honest position here is that this is a legitimate gray zone with reasonable clinical disagreement, and that how to manage it is an individual decision made with a provider who knows your full clinical picture — including symptoms, antibody status, history, and goals.

The thyroid is one of those systems where the conventional tools, when correctly applied, are highly effective, and where the greatest opportunity is often in getting the basics right — correct diagnosis, appropriate hormone replacement when indicated, nutritional foundations (selenium particularly), trigger investigation for autoimmune flares, and careful attention to what other interventions might shift the hormonal picture. An endocrinology specialist is the right partner for thyroid management. The adjunctive questions — about immunomodulation in Hashimoto's, about the gut-thyroid connection, about how GH-axis or GLP-1 compounds interact with your thyroid status — are worth bringing into that conversation rather than exploring in parallel without that oversight.

When the thyroid is running quietly wrong, everything runs a little harder than it should. Getting that piece right is foundational to the rest of the system. The peptide questions come after, not instead of, that foundation being built.